CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform

Foundational technology developed by UCLA for the Company’s Universal Cancer Vaccine can be adapted to function as an in-vivo CAR-T cell platform to dramatically lower the cost of CAR-T cell cancer therapies

LEHI, Utah, Sept. 12, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies.

CAR-T cell therapy is a type of immunotherapy treatment in which a patient’s T-cells are genetically modified in the laboratory, then reinjected back into the patient, so they will bind to specific proteins (antigens) found on cancer cells and kill them. These modified T-cells are called Chimeric Antigen Receptor (CAR) T Cells. Conventional CAR-T Cell therapy can cost more than $500,000 per dose due to complicated and expensive lab processes. We believe we can dramatically lower the cost to a few thousand dollars per dose by simply helping the body make its own CAR-T cells.

During a remarkable meeting with Company executives recently, the UCLA research team reported significant project progress. Based on their recent findings, it is now clear that the foundational nanoparticle technology developed for the current Universal Cancer Vaccine project, can be easily adapted to target T-cells and carry genetic instructions to reprogram T-cells into CAR-T cells inside the body (in-vivo). Depending on the specific genetic instructions provided, different cancers can be targeted by the new CAR-T cells. Preliminary lab test suggests that this is easy to do. As a result, the Company has decided to expand its development pipeline to include a “Universal CAR-T Platform”.

Conventional CAR-T Cell Therapy Steps:

1. A patient’s T cells are removed from their blood.
2. The gene for a special receptor called chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory by gene editing. The gene forces the T cell to express a protein (receptor) on its surface that binds to the cancer cell’s surface protein (antigen).
3. Millions of CAR-T cells are grown in the laboratory.
4. They are then given to the patient by intravenous infusion.
5. The CAR protein on the surface of the CAR-T cells bind to antigens on the cancer cells and kill them.

CancerVAX Envisioned CAR-T Cell Steps:

1. Genetic codes for targeting specific proteins on cancer cells are loaded into a smart nanoparticle using an innovative high-speed, low-cost manufacturing process.
2. Millions of nanoparticles are injected into the patient as a shot. The nanoparticles attach to the patient’s natural T-cells inside the body, unload the genetic code, and reprogram the T-cells to target specific cancer cells and kill them.

The Company’s pipeline of three projects with UCLA now includes:

1. Children’s Cancer – Immunotherapy treatments for Ewing sarcoma, a children’s bone and tissue cancer with 100% death rate for recurrence.
2. Universal Cancer Vaccine Platform – A novel and customizable Universal Cancer Vaccine (UCV), to be delivered as a shot, that can uniquely detect, mark and kill only cancer cells.
3. Universal CAR-T Cell Platform – A novel and customizable low-cost treatment, to be delivered as a shot, that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells.

Ryan Davies, CEO of CancerVAX commented, “CAR-T cell therapy is one of the more promising immunotherapies entering the mainstream of cancer treatment. There are currently six FDA approved CAR-T cell therapies, and they all cost around $500,000 per dose. While no amount of money is too much to save a single human life, we hope to dramatically lower the cost of CAR-T cell therapy by several orders of magnitude and help save many lives. The extreme low cost of the COVID vaccine, which uses similar technology and concepts, leads us to believe that this major cost reduction is possible with our Universal CAR-T Cell platform.”

For more information about CancerVAX, please visit http://www.cancervax.com/.

About Us

CancerVAX, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer. Working with a team of experienced cancer researchers and physicians at UCLA, we are developing a pipeline that includes three innovative projects: (1) treating Ewing sarcoma, a deadly children’s cancer, (2) a Universal Cancer Vaccine that will detect, mark, and destroy only cancer cells while leaving healthy cells in-tact, and (3) a low cost Universal CAR-T Cell Platform that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells. All of our immunotherapy technologies are designed to be delivered as injections. We look forward to the day when treating cancer will be as simple as getting a flu shot – a better way to treat cancer.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

Press Contact:
CancerVAX, Inc.
Tel: (805) 356-1810
communications@CancerVAX.com